[ Business | US Market | Industry | IPO | S&P | International | PRNews | BizWire | Finance Home ]
---------------------------------------
Tuesday April 28, 8:21 am Eastern TimeCompany Press ReleaseSOURCE: Biolase Technology, Inc.BioLase is Awarded Patent for New Non-Thermal Laser Technology New Method Uses Water -- Not Thermal Heat -- To Cut Hard, Soft Tissue; Consumers Likely to See First Applications in Wrinkle Removal, Reduced-Pain Dentistry
SAN CLEMENTE, Calif., April 28 /PRNewswire/ -- BIOLASE TECHNOLOGY, INC. (Nasdaq: BLTI - news) today announced that it had received a patent from the U.S. Patent and Trademark Office for its pioneering laser ''cool-cutting'' technology which uses water particles -- not thermal heat -- to cut both hard and soft human tissue. Virtually all traditional laser technologies currently on the market use thermal heat to bum away tissue in medical and dental applications.
On April 21, 1998, the U.S. Patent Office granted BioLase a broad patent for HydroKinetic(TM) Laser Cutting Technology. In simplest terms, the HydroKinetic(TM) Laser Tissue Cutting Technology combines the power of the laser with water to form high speed, atomized water particles that act as a cutting tool for removal of hard and soft tissue. The result is that a patient's pain is greatly reduced and often eliminated since water, not thermal heat is used to cut or drill.
''This is a historic moment in our company's development. On one hand it opens the door for us to install this technology in a wide range of medical and industrial arenas and at the same time closes the door on the competition. The patent moves us closer to establishing BioLase's cool-cutting technology as the industry standard,'' said Donald A. La Point, President and CEO of the publicly traded BioLase Technology, Inc. He expects similar grantings of patent applications outside the United States, including critical markets such as Europe and the Pacific Rim.
Federico Pignatelli, the Chairman of the Board of BioLase Technologies, Inc. said that ''this is a very broad patent and it adds tremendous value to our patent portfolio. In addition, it gives us the opportunity to enter markets outside the medical fields through corporate partnerships and joint ventures. For non-medical applications, BioLase is exploring possible licensing agreements with the lucrative semiconductor industry. Here the same HydroKinetic(TM) technology could be used in 'cleaning and etching' semiconductors rather than using the harsher, environmentally unfriendly acid washes which are currently employed.''
LaPoint said that while there are far-reaching applications for medicine and industry, the newly patented technology most likely would be applied first to dermatology and dentistry. Specifically, the company anticipates launching its new DermaLase(TM) Er,Cr.YSGG laser system which uses the HydroKinetic(TM) technology for tumor and cyst removal, diagnostic biopsies and skin resurfacing (wrinkle removal). DermaLase(TM) received Food and Drug Administration approval last year. In dentistry, BioLase's Millennium(TM) HydroKinetic(TM) Tissue Cutting Technology for dentistry, is currently a waiting FDA approval for hard tissue.
Other areas where BioLase is reviewing potential is in veterinary dentistry, neurosurgery, podiatry, orthopedics and the skin graft industry.
BIOLASE Technology, Inc. manufactures and markets advanced cosmetic, aesthetic, dental and surgical products, including laser systems, HydroKinetic surgical cutting systems, and develops specialized biomaterials for dentistry and other medical specialties. The Company's products incorporate patented and patent-pending technologies that permit achievement of unique results.
The matters discussed in this news release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission, including the reports on Forms 1O-KSB and 1O-Q. Actual results may differ materially from those projected. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE: Biolase Technology, Inc.
---------------------------------------
More Quotes and News:Biolase Technology Inc (Nasdaq:BLTI - news)Related News Categories: medical/pharmaceutical
---------------------------------------
Help
---------------------------------------
Copyright c 1998 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
See our Important Disclaimers and Legal Information.
Questions or Comments? |
